Fig. 3: LS mean change from baseline in PANSS subscale score (mITT population). | npj Schizophrenia

Fig. 3: LS mean change from baseline in PANSS subscale score (mITT population).

From: Efficacy and safety of once-monthly Risperidone ISM® in schizophrenic patients with an acute exacerbation

Fig. 3

a PANSS positive subscale, where mean PANSS positive subscale score at baseline for placebo = 25.3 (SD: 3.11), for Risperidone ISM 75 mg = 25.1 (SD: 3.15) and for Risperidone ISM 100 mg = 25.5 (SD: 3.40). The error bars represent SE and P values are for Risperidone ISM 75 mg and Risperidone ISM 100 mg dose group versus placebo (*p < 0.05, **p < 0.001, ***p < 0.0001). b PANSS Negative Subscale, where mean PANSS score at baseline for placebo = 23.5 (SD: 3.34), for Risperidone ISM 75 mg = 23.3 (SD: 4.19) and for Risperidone ISM 100 mg = 23.1 (SD: 3.73). The error bars represent SE and P values are for Risperidone ISM 75 mg and Risperidone ISM 100 mg dose group versus placebo (*p < 0.05, **p < 0.01, ***p < 0.001). c PANSS General Psychopathology Subscale, where Mean PANSS Score at baseline: for placebo = 47.7 (SD: 4.90), for Risperidone ISM 75 mg = 47.8 (SD: 5.48) and for Risperidone ISM 100 mg = 47.4 (SD: 5.06). The error bars represent SE and P values are for Risperidone ISM 75 mg and Risperidone ISM 100 mg dose group versus placebo (*p < 0.05, **p < 0.001, *** p < 0.0001).

Back to article page